

REMARKS

The Official Action of July 9, 2008 has been carefully considered. The amendments and remarks herein are considered to be responsive thereto. The claims
5 remaining in the case are 1-10, and 13-16.

Claims 1-5 & 7 are rejected under 35 USC 112, first paragraph because the specification is not enabling for the variable Het/Ar when it is other than pyridine. Claim 1 is herein amended to recite that Het/Ar is phenyl, naphthyl, phenanthrenyl, or pyridyl without prejudice to refile on the other Het/Ar substituents. No new matter
10 has been added. In light of what is known in the chemical arts the ordinary skilled artisan would readily understand and be able to practice the invention as currently claimed without undue experimentation. This is particularly true when he/she considers Schemes 1 through 3.

Claim 11 and 12 are rejected under 35 USC section 112, first paragraph
15 because the specification does not provide enablement for the treatment of Alzheimer's, and diabetes. Claims 11 and 12 have been deleted without prejudice to refile.

Claims 6, 9, 10, and 13-16 are objected to as being dependent upon a rejected base claim. Pursuant to the arguments and amendments to the claims made
20 herein, Applicants respectfully submit that the claims now depend upon an allowable claim.

In light of the amendments and remarks herein Applicants believe the claims are in condition for allowance. The Examiner is respectfully requested to contact the undersigned at the number below if this would expedite the allowance.

25

30

35

Respectfully submitted,

By: 

Sylvia A. Ayler

Reg. No. 36,436

Attorney for Applicant(s)

MERCK & CO., INC.

P.O. Box 2000

Rahway, New Jersey 07065-0907

(732) 594-4909

Date: July 30, 2008